尤瑞克林与丁苯酞治疗急性脑梗死患者的效果

doi:10.3760/cma.j.issn.1007-1245.2024.03.012

摘要/Abstract

摘要：

目的　分析尤瑞克林联合丁苯酞对急性脑梗死患者认知功能、血管内皮功能及日常生活能力的影响。方法　本文为随机对照试验，选取2021年3月至2023年3月在巴彦淖尔市医院进行治疗的100例急性脑梗死患者作为研究对象，采用随机数字表法分为观察组和对照组，各50例。对照组男24例、女26例，年龄（60.17±8.92）岁，经静脉滴注尤瑞克林进行治疗；观察组男27例、女23例，年龄（59.45±8.42）岁，在对照组基础上加用丁苯酞进行治疗。对比两组患者临床疗效、治疗前后脑血流参数［血浆黏度、全血黏度、纤维蛋白原（FIB）］、血管内皮功能［血管内皮生长因子（VEGF）、内皮素-1（ET-1）、一氧化氮（NO）］、蒙特利尔认知评估量表（MoCA）、改良Barthel指数（MBI）评分以及不良反应发生情况。统计学方法采用独立样本t检验、配对t检验、χ²检验。结果　观察组总有效率为92.00%（46/50），高于对照组的76.00%（38/50），差异有统计学意义（χ²=4.962，P=0.029）。治疗后，观察组血浆黏度、全血黏度及FIB水平［（1.74±0.52）mPa•s、（16.59±6.33）mPa•s、（2.34±0.78）g/L］均低于对照组［（2.05±0.60）mPa•s、（21.37±6.54）mPa•s、（2.93±0.72）g/L］，差异均有统计学意义（t=2.761、3.714、3.930，均P<0.05）。治疗后，观察组ET-1指标［（48.53±5.49）ng/L］低于对照组［（54.61±6.52）ng/L］，NO、VEGF指标［（45.54±6.80）μmol/L、（54.21±8.35）ng/L］均高于对照组［（38.22±5.71）μmol/L、（49.64±6.08）ng/L］，差异均有统计学意义（t=5.044、5.829、3.129，均P<0.05）。治疗后，观察组MBI、MoCA评分［（68.37±12.54）分、（24.67±3.21）分］均高于对照组［（55.91±11.47）分、（21.13±3.95）分］，NIHSS评分［（7.65±1.13）分］低于对照组［（10.21±1.84）分］，差异均有统计学意义（t=5.184、4.918、8.383，均P<0.05）。观察组不良反应发生率［14.00%（7/50）］与对照组［10.00%（5/50）］比较，差异无统计学意义（χ²=0.379，P=0.538）。结论　尤瑞克林联合丁苯酞治疗急性脑梗死，可提高治疗效果，改善脑部微循环及血管内皮功能，促进患者认知功能、日常生活能力恢复，具有较高安全性，值得临床推广。

关键词:

脑梗死, 尤瑞克林, 丁苯酞, 认知功能, 血管内皮功能, 日常生活能力

Abstract:

Objective　To analyze the effects of eurecline and butylphthalein on cognitive function, vascular endothelial function, and daily living ability in patients with acute cerebral infarction. Methods　A total of 100 patients with acute cerebral infarction treated in Bayannur City Hospital from March 2021 to March 2023 were selected for the randomized controlled trial, and were divided into an observation group and a control group by lottery, with 50 cases in each group. There were 24 males and 26 females in the control group; they were (60.17±8.92) years old. There were 27 males and 23 females in the control group; they were (59.45±8.42) years old. The control group took intravenous infusion of eurekline. The observation group took eurecline and butylphthalein. The clinical efficacies, cerebral blood flow parameters [plasma viscosity, whole blood viscosity, fibrinogen (FIB)], vascular endothelial function [vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), and nitric oxide (NO)], and scores of Montreal Cognitive Assessment Scale (MoCA) and Modified Barthel Index (MBI) before and after the treatment, and incidences of adverse reactions were compared between the two groups. The independent-sample t test, paired t test, and χ² test were used. Results　The total effective rate of the observation group was significantly higher than that of the control group [92.00% (46/50) vs. 76.00% (38/50)], with a statistical difference (χ²=4.962; P=0.029). After the treatment, the plasma viscosity, whole blood viscosity, and level of FIB in the observation group were lower than those in the control group [(1.74±0.52) mPa·s vs. (2.05±0.60) mPa·s, (16.59±6.33) mPa·s vs. (21.37±6.54) mPa·s, and (2.34±0.78) g/L vs. (2.93±0.72) g/L], with statistical differences (t=2.761, 3.714, and 3.930; all P<0.05). After the treatment, the levels of ET-1, NO, and VEGF in the observation group were better than those in the control group [(48.53±5.49) ng/L vs. (54.61±6.52) ng/L, (45.54±6.80) μmol/L vs. (38.22±5.71) μmol/L, and (54.21±8.35) ng/L vs. (49.64±6.08) ng/L], with statistical differences (t=5.044, 5.829, and 3.129; all P<0.05). After the treatment, the scores of MBI, MoCA, and NIHSS in the observation group were better than those in the control group [(68.37±12.54) vs. (55.91±11.47), (24.67±3.21) vs. (21.13±3.95), and (7.65±1.13) vs. (10.21±1.84)], with statistical differences (t=5.184, 4.918, and 8.383; all P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group [14.00% (7/50) vs. 10.00% (5/50); χ²=0.379,P=0.538]. Conclusion　Eurecline combined with butylphthalein for patients with acute cerebral infarction can significantly improve the therapeutic effect and their cerebral microcirculation and vascular endothelial function and promote their recovery of cognitive function and daily living ability, and has high safety, so it is worthy of clinical promotion.

Key words:

Cerebral infarction, Eurecline, Butylphthalein, Cognitive function, Vascular endothelial function, Daily living ability

王灵芝杜圆圆刘艳.

尤瑞克林与丁苯酞治疗急性脑梗死患者的效果 [J]. 国际医药卫生导报, 2024, 30(3): 409-413.

Wang Lingzhi, Du Yuanyuan, Liu Yan.

Effect of eurecline and butylphthalein for patients with acute cerebral infarction [J]. International Medicine and Health Guidance News, 2024, 30(3): 409-413.

参考文献

[1] Kwok CS, Abbas KS, Qureshi AI, et al. Outcomes for patients hospitalized with acute myocardial infarction and cerebral infarction in the united states: insights from the National Inpatient Sample[J].Intern Emerg Med,2023,18(2):375-383.DOI:10.1007/s11739-022-03172-w.
[2] Zeng J, Wang F, Feng H, et al. Influencing factors of recanalization after intravenous thrombolysis with urokinase in acute cerebral infarction patients[J].Eur Neurol,2020,83(2):162-166.DOI:10.1159/000507288.
[3] Grewal AK, Singh N, Singh TG. Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia-reperfusion-induced injury in mice[J].J Pharm Pharmacol,2019,71(6):956-970.DOI:10.1111/jphp.13073.
[4] 王红霞,胡洪涛,姜明,等. 急性脑梗死患者静脉溶栓前急诊生化与溶栓后早期转归及预后的关系[J]. 中风与神经疾病杂志,2019,36(9):810-814.DOI:10.19845/j.cnki.zfysjjbzz. 2019.09.009.
[5] 付巍,谢立栋,李卓. 注射用尤瑞克林治疗大动脉粥样硬化型急性期脑梗死的临床疗效观察[J]. 中华急诊医学杂志,2019,28(7):905-907.DOI:10.3760/cma.j.issn.1671-0282. 2019.07.023.
[6] 张宝瑞,王龙安,秦历杰. 丁苯酞联合溶栓治疗老年人急性脑梗死的疗效分析[J]. 中华老年医学杂志,2021,40(9):1126-1129.DOI:10.3760/cma.j.issn.0254-9026.2021. 09.009.
[7] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国各类主要脑血管病诊断要点2019[J]. 中华神经科杂志,2019,52(9):710-715.DOI:10.3760/cma.j.issn.1006?7876.2019.09.003.
[8] 蔡业峰,贾真,张新春,等. 美国国立卫生院卒中量表(NIHSS)中文版多中心测评研究——附537例缺血中风多中心多时点临床测评研究[J]. 北京中医药大学学报,2008,31(7):494-498. DOI:10.3321/j.issn:1006-2157.2008.07.017.
[9] 孔伶俐,孙忠国,周田田,等. 蒙特利尔认知评估量表在轻度认知功能障碍诊断中的应用[J]. 中国健康心理学杂志,2015(8):1212-1214,1215.DOI:10.13342/j.cnki.cjhp.2015.08.026.
[10] 闵瑜,吴媛媛,燕铁斌. 改良Barthel指数(简体中文版)量表评定脑卒中患者日常生活活动能力的效度和信度研究[J]. 中华物理医学与康复杂志,2008,30(3):185-188. DOI:10.3321/j.issn:0254-1424.2008.03.010.
[11] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.DOI:10.3760/cma.j.issn.1006-7876.2018.09.004.
[12] Zhang Y, Jiang L, Yang P, et al. Comparison of lymphocyte count, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting the severity and the clinical outcomes of acute cerebral infarction patients[J].Clin Lab,2019,65(7):1277-1283.DOI:10.7754/Clin.Lab. 2019.190102.
[13] 梁菊萍,杨旸,董继存. 急性脑梗死患者流行病学调查及危险因素[J]. 中国老年学杂志,2021,41(12):2484-2487.DOI:10.3969/j.issn.1005-9202.2021.12.007.
[14] 吴川杰,吴隆飞,孙程贺,等. 术前抗血小板聚集治疗对大血管闭塞性急性脑梗死患者机械取栓术后安全性和有效性的影响[J]. 中国脑血管病杂志,2022,19(5):299-305,338.DOI:10.3969/j.issn.1672-5921.2022.05.002.
[15] 李波,张婷,周遥,等. 尤瑞克林联合阿替普酶静脉溶栓对急性脑梗死患者神经功能及血液流变学的影响[J]. 中国现代医学杂志,2022,32(24):74-78.DOI:10.3969/j.issn.1005- 8982. 2022.24.012.
[16] 肖海燕,杨淑贤,韩雯,等. 丁苯酞及其衍生物药理学研究进展[J]. 中国中药杂志,2022,47(13):3425-3431.DOI:10.19540/j.cnki.cjcmm.20220117.701.
[17] 杨东娜,张涤,于佳佳. 丁苯酞注射液联合依达拉奉对老年急性脑梗死患者细胞因子、血管内皮功能和氧化应激的影响[J]. 中国老年学杂志,2021,41(3):477-480.DOI:10.3969/j.issn.1005-9202.2021.03.008.
[18] 欧阳欣,胡巧霞,高大鹏. 丁苯酞注射液对急性脑梗死合并颅内动脉狭窄患者颅内动脉血流动力学、氧化应激及血清Hcy和CysC水平的影响[J]. 中国老年学杂志,2020,40(12):2485-2487.DOI:10.3969/j.issn.1005-9202. 2020.12.006.
[19] Zhou M, Huang Z. Effect of comprehensive cerebral protection program on cerebral oxygen metabolism and vascular endothelial function in elderly patients with acute cerebral infarction[J].Iran J Public Health,2019,48(2):299-304.
[20] Chan SJ, Esposito E, Hayakawa K, et al. Vascular endothelial growth factor 165-binding heparan sulfate promotes functional recovery from cerebral ischemia[J].Stroke,2020,51(9):2844-2853.DOI:10.1161/STROKEAHA. 119.025304.
[21] 孙洲,曹非,骆芳,等. 尤瑞克林对急性脑缺血再灌注大鼠血管新生因子表达的影响[J]. 中国老年学杂志,2019,39(19):4797-4799.DOI:10.3969/j.issn.1005-9202.2019.19.052.
[22] 李丽,喻伟. 阿替普酶联合尤瑞克林对急性脑梗死的疗效及对脑血管储备功能影响[J]. 中国临床药理学杂志,2021,37(24):3307-3310.DOI:10.13699/j.cnki.1001-6821. 2021.24.001.
[23] 贝筝,陈怡,龙登毅,等. 丁苯酞联合依达拉奉治疗急性脑梗死患者神经功能及血管内皮功能的影响[J]. 脑与神经疾病杂志,2019,27(1):5-9.
[24] 柯维春,苏庆杰,吴浩. 丁苯酞联合尤瑞克林治疗脑卒中后认知功能障碍临床观察[J]. 中国药业,2022,31(13):94-96.DOI:10.3969/j.issn.1006-4931.2022.13.022.
[25] 刘惠钦,李伟峰,范月辉,等. 尤瑞克林联合丁苯酞对动脉粥样硬化性脑梗死患者的影响[J]. 实用临床医药杂志,2022,26(6):43-46.DOI:10.7619/jcmp.20213880.
[26] 甄诚,曹宾,刘明,等. 丁苯酞和尤瑞克林联合治疗老年脑梗死进展期患者疗效及对患者凝血功能和神经功能缺损的影响[J]. 实用医院临床杂志,2020,17(2):116-119.DOI:10.3969/j.issn.1672-6170.2020.02.035.